Guy Van Meter joins Adimab
This article was originally published in Scrip
Adimab, a US biotechnology company developing an integrated yeast-based antibody discovery and maturation platform, has appointed Guy Van Meter senior director, head of business development. He joins from Pfizer, where he was involved in new business initiatives around RNAi therapeutics and regenerative medicine for Pfizer's Biotherapeutics and Bioinnovation Center in San Francisco.
You may also be interested in...
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.